Docket No. ORT-1453

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-11 (canceled)

Claim 12 (currently amended) A The method of claim 10 for treating impaired oral glucose tolerance in a mammal afflicted with such condition comprising administering to said mammal a therapeutically effective amount of a compound of the formula I:

$$\begin{array}{c|c} R^5 & \xrightarrow{X} CH_2OSO_2NHR^1 \\ \hline R^2 & \\ \hline R^4 & R^3 & \\ \hline \end{array}$$

wherein

X is CH2 or oxygen;

R1 is hydrogen or alkyl; and

R2, R3, R4 and R5 are independently hydrogen or lower alkyl and, when X is CH2, R4 and R5 may be alkene groups joined to form a benzene ring and, when X is oxygen, R2 and R3 and/or R4 and R5 together may be a methylenedioxy group of the following formula (II):

wherein

R⁶ and R⁷ are the same or different and are hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or

Docket No. ORT-1453

cyclohexyl ring, wherein the therapeutically effective amount is from about 10 to 1000 mg daily.

Claim 13 (currently amended) The method of claim 1012, wherein the therapeutically effective amount is from about 10 to 650 mg dailv.

Claim 14 (currently amended) The method of claim 1012, wherein the amount is of from about 16 to 325 mg once or twice daily.

Claims 15-21 (canceled)

Claim 22 (currently amended) AThe method of Claim 20 for improving defective insulin sensitivity in a mammal afflicted with such condition with comprising administering to said mammal a therapeutically effective amount of a compound of the formula I:

$$R^{5} \xrightarrow{X} CH_{2}OSO_{2}NHR^{1}$$

$$R^{4} \qquad R^{3} \qquad (I)$$

wherein

X is CH2 or oxygen;

R1 is hydrogen or alkyl; and

 \mathbb{R}^2 , \mathbb{R}^3 , \mathbb{R}^4 and \mathbb{R}^5 are independently hydrogen or lower alkyl and, when X is CH2, R4 and R5 may be alkene groups joined to form a benzene ring and, when X is oxygen, R2 and R3 and/or R4 and R5 together may be a methylenedioxy group of the following formula (II):

$$\mathbb{R}^{7}$$
 0 (II)

Docket No. ORT-1453

wherein

R⁶ and R⁷ are the same or different and are hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring, wherein the therapeutically effective amount is from about 10 to 1000 mg daily.

Claim 23 (currently amended) The method of claim $\frac{2022}{10}$, wherein the therapeutically effective amount is from about 10 to 650 mg daily.

Claim 24 (currently amended) The method of claim 2022, wherein the amount is of from about 16 to 325 mg once or twice daily.